Composition for nonalcoholic fatty liver disease (NAFLD)
The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
1. A method of treating non-alcoholic steatohepatitis, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable salt of
wherein R is —S-methyl, to treat the non-alcoholic steatohepatitis.
2. The method of claim 1 , wherein the pharmaceutically acceptable salt is a metal cation salt.
3. The method of claim 1 , wherein the pharmaceutically acceptable salt is a metal cation salt selected from the group consisting of a sodium salt, potassium salt, calcium salt, and magnesium salt.
4. The method of claim 1 , wherein the pharmaceutically acceptable salt is a magnesium salt.
5. A method of treating non-alcoholic steatohepatitis, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and
wherein R is —S-methyl, and M + is a metal cation, to treat the non-alcoholic steatohepatitis.
6. The method of claim 5 , wherein M + is Mg 2+ .